HIMS (Health)

Incheon, South Korea Industrials Public

HIMS Co., Ltd. is a South Korean manufacturer of machine vision, optical inspection, and automation equipment headquartered in Incheon. Founded in 1999, the company develops and supplies inspection modules and machines for the display, semiconductor, and factory-automation (FA) industries. It is best known for OLED display equipment, including divided/fine metal mask (FMM) related machines, welders, inspection systems, and repair equipment used in the organic deposition process by global display panel makers. HIMS also produces vision modules and vision components and has expanded into AI/deep-learning-based inspection and smart factory solutions. The company is listed on the KOSDAQ market under ticker 238490.

Public Company

HIMS (Health) is publicly traded

This company is no longer available on our private secondary market. Shares can be traded publicly under its listed ticker.

Overview

Company data and valuation marks are estimates and may be incomplete, stale, erroneous, or revised.

Founded

1999

Employees

201–500

Total Funding

$157M

3 rounds

Latest Valuation

$1.1B

January 28, 2019

Funding

Total raised $157M across 3 rounds

Funding data and valuation marks are estimates and may be incomplete, stale, erroneous, or revised.

Last updated 06-25-2026

Latest Round

Type

Series C

Date

January 28, 2019

Amount

$100M

Valuation

$1.1B

DateRoundAmount RaisedValuationLead Investors
January 28, 2019 Series C $100M $1.1B
June 28, 2018 Series B $50M
November 2, 2017 Series A $7M Thrive Capital, Forerunner Ventures

Leadership

  • Ju Hoan Kim

    Chief Executive Officer

Competitors

Competitor list is illustrative and may be incomplete, stale, or erroneous.

  • Teladoc Health

    Leading telehealth platform with 52M+ members, offering virtual medical visits, chronic care programs, and BetterHelp online therapy services.

  • Amazon One Medical

    Amazon-backed primary care platform with integrated telehealth services offering pay-per-visit consultations ($29-$49) in direct competition with Hims.

  • Ro (Roman)

    Direct-to-consumer telehealth platform offering consultations and prescription delivery services across multiple medical specialties.

  • CVS Caremark

    Pharmacy Benefits Manager expanding digital health services; becoming a more direct competitor as CVS continues digitalization efforts.

  • Nurx

    Digital health platform offering telehealth consultations and prescription delivery services primarily focused on women's health.

  • Lemonaid Health

    Online telehealth platform providing virtual consultations and prescription delivery services for common health conditions.

HIMS (Health) Investment FAQ

HIMS (Health) FAQ

Hims & Hers Health completed its merger with Oaktree Acquisition Corp. (SPAC) and began trading on the New York Stock Exchange under ticker HIMS on January 21, 2021. The company is a publicly traded, multi-specialty telehealth platform with over 2.5 million subscribers and achieved 59% revenue growth in 2025, reaching approximately $2.35B in annual revenue.

HIMS (Health) shares can be purchased through any standard brokerage account — including Fidelity, Charles Schwab, TD Ameritrade, and online platforms like Robinhood or E*TRADE. Search for the ticker to place an order.

HIMS (Health) had a valuation of approximately $1.1B at the time of its public offering. Current market capitalization fluctuates with the share price.

HIMS (Health) raised $157M across 3 disclosed funding rounds prior to its public listing.

HIMS (Health) is headquartered in Incheon, South Korea.

Access live market data

Sign Up

Data collected with AI, which can make mistakes. Please double-check this information.